ITI Pharma and Healthcare Fund - Direct Plan - Growth Option
ITI Asset Management Limited · Direct Plan · Growth
Fund overview
0.50% on or before 3M, NIL after 3M
Returns & rankings
| Period | Fund Returns | Category Avg. | Rank | VS Category |
|---|---|---|---|---|
| … | ||||
Green = fund outperformed the category average for that period; red = underperformed. Periods under 1 year always show absolute (non-annualised) returns. Past performance does not guarantee future returns.
Return calculator
One-time investment
₹5,000
| Over the past | Total investment | Would've become | Returns |
|---|---|---|---|
| 1 Year | ₹5,000 | ₹5,660 | +660 |
| 3 Years | ₹5,000 | ₹7,255 | +2,255 |
| 5 Years | ₹5,000 | ₹9,298 | +4,298 |
Calculated using the fund's annualised return since inception (13.2% p.a.) as period-wise historical returns aren't available in the current feed. Actual returns fluctuate and are not guaranteed. Mutual fund investments are subject to market risks.
Holdings
37 securitiesTop 10 holdings make up 53.2% of the portfolio.
| Security | Sector | Market Cap | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals & Biotechnology | Large Cap | 11.96% |
| Divi'S Laboratories Ltd | Pharmaceuticals & Biotechnology | Large Cap | 9.51% |
| Apollo Hospitals Enterprises Ltd | Healthcare Services | Large Cap | 5.45% |
| Torrent Pharmaceuticals Ltd | Pharmaceuticals & Biotechnology | Large Cap | 4.78% |
| Dr. Reddys Laboratories Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.78% |
| Max Healthcare Institute Ltd | Healthcare Services | Mid Cap | 4.49% |
| Cipla Ltd | Pharmaceuticals & Biotechnology | Large Cap | 4.19% |
| Laurus Labs Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.02% |
| Aurobindo Pharma Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.01% |
| Mankind Pharma Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 3.78% |
Portfolio Allocation
Equity / Debt / Cash
Total Value
₹266 Cr
Market Cap Split
Total Value
100%
Equity sector allocation
Total Value
₹264 Cr
Exit load, stamp duty & tax
08-Nov-21
0.50% on or before 3M, NIL after 3M
0.005% (from July 1st, 2020)
Taxation depends on the fund category and holding period. Consult the scheme document or a tax advisor for details.
Risk & Performance Ratios (1Y)
| Standard Deviation | 14.38% |
| Beta | 0.86 |
| Sharpe Ratio | 2.57 |
| Sortino Ratio | -0.17 |
| Treynor Ratio | 0.43 |
| Jensen's Alpha | 2.62 |
| Information Ratio | -0.16 |
| R-Squared | 95.90% |
| Max Drawdown | -4.39% |
| Upside Capture | 89.39% |
| Downside Capture | 77.68% |
Fund management
Scheme Details
Investment objective
The Investment Objective Of The Scheme Is To Seek To Generate Long Term Capital Appreciation Throughinvesting In Equity And Equity Related Securities Of Companies Engaged In Pharma And Healthcare.However, There Can Be No Assurance Or Guarantee That The Investment Objective Of The Scheme Would Be Achieved.
Fund house
ITI Asset Management Limited
Frequently asked questions
What is the NAV of ITI Pharma and Healthcare Fund - Direct Plan - Growth Option?
The NAV of ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is ₹18.49 as of 21 Oct 2026. NAV is updated at the end of every trading day.
How much expense ratio is charged by ITI Pharma and Healthcare Fund - Direct Plan - Growth Option?
The expense ratio charged by ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is 0.92%.
What is the Min. SIP of ITI Pharma and Healthcare Fund - Direct Plan - Growth Option?
The minimum SIP investment in ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is ₹500 per month.
What is the Min. Lumpsum of ITI Pharma and Healthcare Fund - Direct Plan - Growth Option?
The minimum lumpsum investment in ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is ₹5,000.
What is the Exit Load of ITI Pharma and Healthcare Fund - Direct Plan - Growth Option?
The exit load for ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is: 0.50% on or before 3M, NIL after 3M
.svg){kind=small}